Table 5.
Literature reviews regarding the efficacy of IFN treatment for hepatitis B for children1.
| Author | time | Treatment | Duration | Patient | N | Results |
|---|---|---|---|---|---|---|
| Sokal (9) | 1998 | IFN α-2b | 48W | children | 144 | HBeAg clearance:26% |
| Hu (10) | 2019 | IFN α-2b vs peg-IFN α-2a | 48W | children | 36 | HBsAg clearance: 22.2% vs. 11.1% |
| Zhu (11) | 2018 | IFN+LAM | 96W | Immune tolerant |
69 | HBeAg seroconversion: 32.61% HBsAg clearance: 21.74% |
| Bortolottia (3) | 2000 | IFN α-2a | 3-6 months | children | 107 | HBsAg clearance:25% for responders (16 patients) |
| Fan (12) | 2019 | peg-IFN α-2a | 48W | children | 41 | HBeAg clearance: 66.7% HBsAg clearance: 52% |
| Rosenthal (13) | 2019 | peg-IFN α-2a +ETV | 48W | Immune tolerant |
60 | HBsAg clearance:3% |
| Wang (14) | 2021 | IFN α | 72W | Immune active |
411 | HBeAg clearance:39.87% HBsAg clearance:11.08% |
| Choe (15) | 2007 | IFN α+ LAM | 12 months | children | 59 | HBeAg clearance:65% |
| D’Antiga (16) | 2006 | IFN α+LAM | 10 months | Immune tolerant |
23 | HBsAg seroconversion:17% |
| Paddar (17) | 2012 | IFN α+LAM | 52 weeks | Immune tolerant |
28 | HBsAg seroconversion:21.4% |
1(peg-IFN), pegylated interferon; (LAM), lamivudine; (HBsAg), hepatitis B surface antigen; (HBeAg), hepatitis B e antigen.